
Opinion|Videos|October 21, 2024
Use of Bone Protection Agents
Author(s)Neal D. Shore, MD, Petros Grivas MD, PhD
Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.
Advertisement
Episodes in this series

Do you mandate for an mcrpc that all your patients on a bone health agent and antiresorptive, regardless of the therapy, and regardless of whether they have bone lesions?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


